Abstract
Background: The predictive role of radiological and histological classification of
giant cell bone tumors has been disputed. Moreover, some malignant tumors
including sarcoma and carcinoma harbor similarity with giant cell bone tumors.
Application of molecular biomarkers can help to avoid these mimics and share for
better understanding of its biological behavior. The current study investigates the
immuno-histochemical expression of cyclinD1 and CD10 in giant cell bone tumors
and analyzes their relation with clinico-pathological findings.
Method: Immuno-histochemical expression of cyclinD1 and CD10 in 25
specimens of giant cell bone tumors were studied. The relationship between their
expression and the clinico-pathological variables were also investigated.
Results: Nuclear cyclinD1 immuno-staining was observed in 40% of multi
nuclear giant cells and complete absence in stromal cells in the same time the
study found a statistical correlation between its expression and both of recurrence
(p=0.001) and aggressiveness (p=0.012) of studied cases. Membranous CD10
immuno-expression was exclusively observed in 80% of stromal mononuclear cells
with significant correlation with aggressiveness (p=0.23) and recurrence (p=0.014).
Conclusion: Although histological classification provides different histological
findings of giant cell bone tumor, molecular markers (cyclin D1 and CD10) could
be considered as independent predicting factors for GCT. Cyclin D1 can be
considered as a prognostic marker to predict its behavior .CD10 is exclusively
expressed in the neoplastic mononuclear cells , raising its possible role in the
giant cell bone tumor pathogenesis . |
